Xeljanz is one of the most widely used drugs on the market today. The drug has been used to treat a variety of diseases, including cancer, blood clots and heart problems. But a recent study has found that Xeljanz has a number of negative side effects that could increase the risk of cancer and blood clots. In addition, the drug has been recalled.

Increased risk of blood clots

Xeljanz (tofacitinib) has been linked to an increased risk of blood clots in the lungs. Blood clots are a serious health problem and can cause life-threatening complications. They can travel to other parts of the body and can cause irreversible damage to organs. They also cause swelling and lightheadedness.

Xeljanz is part of a class of drugs called JAK inhibitors, which have an inherent risk of serious adverse cardiovascular events. They are used to treat rheumatoid arthritis and ulcerative colitis.

The FDA announced in February that Xeljanz may increase the risk of blood clots in the legs and lungs. They are more likely to occur in people who take the drug, especially those who are older or at high risk for cardiovascular disease. The warning was based on an ongoing study.

The FDA reviewed a large randomized clinical trial. Researchers found that Xeljanz at 10-mg twice daily increased the risk of pulmonary embolism. The FDA also found an increased risk of death in some patients.

Increased risk of heart problems

Xeljanz, a popular arthritis medication, is known to increase the risk of heart problems. It is a drug that suppresses the body’s immune system, thereby decreasing inflammation. It is used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

After reviewing Pfizer’s post-marketing Xeljanz safety study trial, the Food and Drug Administration (FDA) issued an alert, warning that Xeljanz may increase the risk of serious heart problems. The warning is based on preliminary results from the study, and comes after the FDA required Pfizer to conduct a randomized safety clinical trial.

Pfizer has been conducting a long-term study of Xeljanz at the direction of the FDA. The company is working with the FDA to review the full results of the study as soon as they become available. In addition, the company will seek additional information on the possible side effects of Xeljanz.

In February, the FDA issued a safety alert, warning that Xeljanz increases the risk of heart problems and cancer. The alert is based on the preliminary results of a study called ORAL Surveillance. The study evaluated cardiovascular risks, blood clots in the lungs, and other potential risks. The study also compared Xeljanz with a tumor necrosis factor (TNF) inhibitor.

Increased risk of cancer

Xeljanz is a drug that is used to treat three autoimmune disorders: rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. This drug is a janus kinase inhibitor, which is an immune system drug that affects how the immune system works. This type of medication has been associated with an increased risk of cancer.

The Food and Drug Administration (FDA) issued a warning about blood clot problems in people taking Xeljanz. The warning was based on a study that evaluated the risk of blood clots in the lungs. The study also examined whether the drug was linked to an increased risk of heart attacks, strokes, and death.

The FDA also warned about the risk of cancer in older patients. Studies showed that Xeljanz patients were more likely to develop cancer than TNF inhibitor patients. This is not the first time that the FDA has issued such a warning about a drug. It is important for patients to take this warning seriously and to talk to their rheumatologist about their risk of developing cancer.

Recall

Xeljanz is a drug that suppresses the immune system. In doing so, it reduces swelling and inflammation. However, it may also cause life-threatening cardiovascular events.

In February 2021, the FDA released a safety alert about Xeljanz. The alert warned of a heightened risk of serious heart problems and cancer. The alert was made after a clinical trial was conducted to study the side effects of the drug. The results showed a higher risk of serious heart events and cancer in patients who took the drug at a higher dose.

The FDA also required Pfizer to place a black box warning on Xeljanz product labels. The black box warns patients of an increased risk of blood clots.

Some patients who took Xeljanz reported DVT and PE. In addition, they also experienced an increased risk of all-cause death. The FDA will wait until more information is available before deciding whether or not to recall Xeljanz.

LEAVE A REPLY

Please enter your comment!
Please enter your name here